Danaher Diagnostics: FDA 510(k) Clearances, Shared Predicate Lineage, and Recall History (1976 to 2026)

Consolidated U.S. FDA 510(k) premarket clearance cohort in Clinical Chemistry (primary filing hub: CA) reconciled with CDRH and openFDA historical recall notices from 1976 to 2026.

Review 736 FDA 510(k) clearances, 164 recalled K-numbers, and 838 cumulative 1976 to 2026 CDRH recall notices for Danaher Diagnostics on Predicate Ledger.

Reconciled U.S. FDA 510(k) and Recall Summary for Danaher Diagnostics
Regulatory MetricVerified Value
Entity ClassificationConsolidated MedTech Parent (19 FDA applicant names)
Clinical Advisory SpecialtyClinical Chemistry (Panel CH)
Cleared FDA 510(k) Submissions (1976 to 2026)736 clearances (340 California, 46.2%)
Cleared 510(k)s Linked to a Recall Notice164 K-numbers (22.28% of cleared cohort)
Cumulative Historical Recall Notices (1976 to 2026)838 notices (5 Class I, 813 Class II, 20 Class III)
Currently Open vs Historical Recall StatusCumulative 1976 to 2026 FDA archive total (838 notices); verify live open vs terminated status per notice in dossier
Implantable and Life-Sustaining Clearances0 implantable (0.0%) and 0 life-sustaining
Median FDA 510(k) Review Duration68 days (90th percentile: 235 days)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Danaher Diagnostics across sibling Meru public-data platforms.

Cumulative recall counts span 1976 to 2026 across U.S. FDA CDRH and openFDA public archives and combine closed historical notices with any currently open field actions. Browse all device cohorts, 20 clinical specialties, Shared 510(k) Predicate Lineage Stage, or reconciliation methodology.

Meru AI Healthcare Data Engineering: Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI → · AI for Healthcare Practice · Healthcare Price & Patent-Cliff Crosswalk Guide.